Skip to main content
73°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immunocore Holdings plc - American Depositary Shares
(NQ:
IMCR
)
35.27
-0.78 (-2.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunocore Holdings plc - American Depositary Shares
< Previous
1
2
3
4
5
6
Next >
Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews
June 02, 2025
Via
Benzinga
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
June 02, 2025
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore reports first quarter financial results and provides a business update
May 07, 2025
From
Immunocore Holdings plc
Via
GlobeNewswire
Analyst Expectations For Immunocore Holdings's Future
April 07, 2025
Via
Benzinga
What Analysts Are Saying About Immunocore Hldgs Stock
February 27, 2025
Via
Benzinga
Earnings Scheduled For February 26, 2025
February 26, 2025
Via
Benzinga
Analyst Expectations For Immunocore Hldgs's Future
January 27, 2025
Via
Benzinga
Navigating 8 Analyst Ratings For Immunocore Hldgs
November 11, 2024
Via
Benzinga
Immunocore to present at upcoming investor conferences
April 02, 2025
From
Immunocore Holdings plc
Via
GlobeNewswire
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
March 20, 2025
Via
Benzinga
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
March 10, 2025
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
March 03, 2025
From
Immunocore Holdings plc
Via
GlobeNewswire
A Closer Look at 9 Analyst Recommendations For Immunocore Hldgs
October 24, 2024
Via
Benzinga
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
February 26, 2025
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
February 19, 2025
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
January 10, 2025
From
Immunocore Holdings plc
Via
GlobeNewswire
Analyst Ratings For Immunocore Hldgs
October 07, 2024
Via
Benzinga
Analyst Expectations For Immunocore Hldgs's Future
September 17, 2024
Via
Benzinga
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
January 02, 2025
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
December 23, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
December 17, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
December 13, 2024
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.
Via
Benzinga
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
December 11, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
December 03, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
3 Fast-Growing Stocks Analysts See Doubling in Price
November 11, 2024
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.
Via
MarketBeat
Immunocore to present at upcoming investor conferences
November 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore reports third quarter financial results and provides a business update
November 06, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
September 17, 2024
Via
Benzinga
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
September 14, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
